Robert W. Baird Begins Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

Investment analysts at Robert W. Baird started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note issued to investors on Friday,Benzinga reports. The firm set an “outperform” rating and a $57.00 price target on the stock. Robert W. Baird’s target price would suggest a potential upside of 131.05% from the company’s previous close.

FTH has been the subject of several other research reports. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. HC Wainwright assumed coverage on Sensei Biotherapeutics in a research report on Monday. They issued a “buy” rating and a $60.00 price objective for the company. Finally, BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.50.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $24.67 on Friday. Sensei Biotherapeutics has a fifty-two week low of $6.32 and a fifty-two week high of $36.76.

Insider Activity

In other news, CFO Brian C. Stephenson bought 9,230 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were acquired at an average price of $24.36 per share, with a total value of $224,842.80. Following the transaction, the chief financial officer owned 17,413 shares in the company, valued at $424,180.68. This represents a 112.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 20,219 shares of company stock valued at $461,379 over the last ninety days. 7.00% of the stock is owned by insiders.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.